NLS Pharmaceutics and Kadimastem Receive Hong Kong Patent for Diabetes Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Should l Buy ?
Patent Grant: Kadimastem has received a patent from the Hong Kong Intellectual Property Department for its proprietary cell selection and enrichment technology related to IsletRx, a therapy for insulin-dependent diabetes.
Global Protection: This new patent complements existing patents in Europe, the United States, and India, enhancing the global protection of IsletRx and its therapeutic potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
